Cadrenal to file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki

Cadrenal Therapeutics, Inc.

Plans to submit RPDD request to FDA for tecarfarin to treat pediatric Kawasaki disease patients with coronary artery aneurysms.
If RPDD granted and tecarfarin approved, eligible for Priority Review Voucher valued ~$200M (recent sales $180M-$205M).
Dual-track strategy: Global Pharma (CAD-1005, Phase 3-ready for HIT) and Rare Disease (tecarfarin for Kawasaki).
Company to present at BIO International Convention June 22-25, 2026, seeking partnerships.
Kawasaki disease is leading cause of acquired heart disease in children; up to 25% untreated develop CAAs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.